Company Adaptive Biotechnologies Corporation
Equities
ADPT
US00650F1093
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.21 USD | +11.07% | -3.60% | -34.49% |
Feb. 15 | JPMorgan Adjusts Price Target on Adaptive Biotechnologies to $8 From $11, Maintains Overweight Rating | MT |
Feb. 15 | Adaptive Biotechnologies' Q4 Loss Widens; Revenue Declines; Shares Down | MT |
Business Summary
Number of employees: 709
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Minimal Residual Disease - Service
60.3
%
| 81 | 43.8 % | 103 | 60.3 % | +26.61% |
Immune Medicine - Collaboration
25.0
%
| 66 | 35.8 % | 43 | 25.0 % | -35.86% |
Immune Medicine - Service
14.7
%
| 32 | 17.1 % | 25 | 14.7 % | -21.46% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 185 | 100.0 % | 170 | 100.0 % | -8.11% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Harlan Robins
FOU | Founder | 51 | 09-09-07 |
Chad Robins
CEO | Chief Executive Officer | 49 | 09-09-07 |
Julie Rubinstein
PSD | President | 52 | 11-03-31 |
Tycho Peterson
DFI | Director of Finance/CFO | 51 | 22-03-08 |
Zhou Yi
CTO | Chief Tech/Sci/R&D Officer | - | - |
Investor Relations Contact | - | - | |
Public Communications Contact | - | - | |
Kyle Piskel
AUD | Comptroller/Controller/Auditor | 40 | 21-10-27 |
Stacy Taylor
LAW | General Counsel | 64 | 19-02-28 |
Sharon Benzeno
PRN | Corporate Officer/Principal | 50 | 14-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Hershberg
BRD | Director/Board Member | 61 | 13-01-31 |
Peter Neupert
BRD | Director/Board Member | 68 | 13-12-31 |
Michael Pellini
BRD | Director/Board Member | 58 | 18-02-12 |
Chad Robins
CEO | Chief Executive Officer | 49 | 09-09-07 |
Michelle Griffin
BRD | Director/Board Member | 58 | 19-02-28 |
Katey Owen
BRD | Director/Board Member | 55 | 21-03-16 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 145,092,271 | 142,101,405 ( 97.94 %) | 0 | 97.94 % |
Company contact information
Adaptive Biotechnologies Corp.
1165 Eastlake Avenue East
98109, Seattle
+206 659 0067
http://www.adaptivebiotech.comSector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.49% | 419M | |
-6.65% | 12.14B | |
+82.29% | 3.94B | |
-14.23% | 2.32B | |
-23.73% | 2.19B | |
-19.45% | 1.63B | |
+32.37% | 1.14B | |
+7.42% | 852M | |
-11.75% | 545M | |
+42.88% | 249M |
- Stock
- Equities
- Stock Adaptive Biotechnologies Corporation - Nasdaq
- Company Adaptive Biotechnologies Corporation